The IBS AS Private Equity Fund III is a combination fund that invests one-third of its commitments in the AlpInvest Secondaries Fund VIII, one-third in the AlpInvest ATOM fund II and one-third in direct co-investments in collaboration with AlpInvest.
The complementary combination of these three funds offers IBS clients an attractive risk-return profile.
AlpInvest is a Dutch Private Equity house, which is part of the Carlyle Group. Since inception, clients of AlpInvest have committed over $70 billion to its funds, split between primary, secondary and co-investment private equity strategies. AlpInvest has a global network, vast experience within the various private equity strategies and built up a strong track record over the years.
The AlpInvest Secondaries Fund VIII is a secondary private equity fund. The fund purchases fund participations from third parties. The focus is on buying participations from high-quality primary private equity managers at a discount on the underlying assets.
The AlpInvest ATOM Fund II is also secondary private equity fund. The fund acquires single-asset secondaries from private equity funds. The focus is on high-quality companies with proven business models. These are companies with solid growth, stable profits and a strong competitive position.
The prospectuses of the closed-end investment funds managed for IBS Fund Management B.V. and those of the underlying master investment funds are available at the request of the participants (in the secure part of the site and via [email protected]).
